Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Netherlands Swaps Germany For Norway To Set Prices

Industry Claims Move Is Unnecessary And Threatens Access

Executive Summary

The Netherlands will secure lower medicine prices by referencing Norway instead of Germany to set maximum prices. 

You may also be interested in...



US Slams Dutch IP Policy

The US embassy in the Netherlands has attacked Dutch policies on compulsory licensing and compounding. Critics have accused it of scaremongering.

US Embassy Slams Dutch Compounding Policy

The US embassy in the Netherlands has attacked Dutch policies on compounding and compulsory licensing. Critics have accused it of scaremongering.

Dutch Heath Minister Accused Of Polarizing Medicine Price Debate

Dutch Health Minister Bruno Bruins has attacked pharmaceutical companies over their drug pricing practices, and has threatened to name and shame one particular firm.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS141456

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel